PeptideStack
5.2kquestions
20kanswers
220users

Is SSA worth the price difference against Chinese Peptide Company on measured results?

Asked 20 Jun 2025Modified 12 months agoViewed 28k times
26

What I have: SSA · Chinese Peptide Company.

The comparison I want does not seem to exist anywhere in a form I can evaluate.

I have read the arguments for each and they do not engage with each other.

So which one, and on what grounds?

vendor-comparison
vendor-comparison

Side-by-side comparison of suppliers on measurable axes - independently confirmed purity and content, lead time, cold-chain handling,…

388 questions
cost-analysis
cost-analysis

Cost arithmetic done honestly: cost per milligram after dead-space loss, list versus net price, comparing a multi-dose vial to a fixed-dose pen,…

260 questions
batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

910 questions
shareeditfollowflag
SW
askedswab_and_wait13k1620 Jun 2025

2 Answers

Accepted answer first, then by votes
18

Accepted answer

Answer first: comparing suppliers is only meaningful if the comparison holds the laboratory, the method and the compound constant, and most published comparisons hold none of them.

To compare properly: order the same compound at the same nominal strength from each supplier, submit all samples to the same laboratory in the same submission if possible, and ask for the same test set on each.

Cost per milligram, adjusted honestly

StepValueNote
Vial price, 10 mg nominal£34.00As advertised
Nominal cost per mg£3.4034 ÷ 10
Measured content9.2 mgIndependent content assay
Cost per actual mg£3.7034 ÷ 9.2
Dead-space loss, 20 draws4 %80 µL of a 2 mL fill
Cost per delivered mg£3.853.70 ÷ 0.96
First vial, with £110 assay£14.85Testing dominates a single vial

The relevant detail is that lead time and lane behaviour are supplier properties too and are easier to compare than analytical ones, because they need no laboratory at all.

Content assay results across the published datasets vary considerably more between suppliers than purity does, which makes content the more discriminating axis.

One laboratory, one method, one submission. Otherwise it is not a comparison.

shareimprove this answerflag
TO
answered · acceptedt_oyelaran79k4825 Jul 2025
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
-2

The relevant point is that two competent laboratories disagree by half a per cent on identical material, which is larger than most of the differences people argue about.

Content is the more discriminating measurement than purity for supplier comparison, because purity clusters tightly among competent suppliers and content does not.

Cost per milligram of actual peptide is the honest price comparison, which means dividing by measured content rather than by label claim.

The ratings on this site are a community opinion average on a ten-point scale and are not reconciled with any other community's figures.

Price per milligram of measured peptide, not per milligram of label claim.

shareimprove this answerflag
JW
answeredj_wierzbicki69k1486 Aug 2025
Worth adding that legal position and enforcement posture are different things. – nkem_obiora 28 days ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.